Defective Pulmonary Innate Immune Responses Post-Stem Cell Transplantation; Review and Results from One Model System by Racquel Domingo-Gonzalez & Bethany B. Moore
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 24 May 2013
doi: 10.3389/fimmu.2013.00126
Defective pulmonary innate immune responses post-stem
cell transplantation; review and results from one model
system
Racquel Domingo-Gonzalez 1 and Bethany B. Moore2,3*
1 Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA
2 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
3 Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA
Edited by:
Zoulfia Allakhverdi, University of
Montreal, Canada
Reviewed by:
Nicole Baumgarth, University of
California Davis, USA
Junji Yodoi, Kyoto University, Japan
*Correspondence:
Bethany B. Moore, University of
Michigan, 4053 Biomedical Science
Research Building, 109 Zina Pitcher
Place, Ann Arbor, MI 48109-2200,
USA.
e-mail: bmoore@umich.edu
Infectious pulmonary complications limit the success of hematopoietic stem cell trans-
plantation (HSCT) as a therapy for malignant and non-malignant disorders. Susceptibility
to pathogens in both autologous and allogeneic HSCT recipients persists despite suc-
cessful immune reconstitution. As studying the causal effects of these immune defects
in the human population can be limiting, a bone marrow transplant (BMT) mouse model
can be used to understand the defect in mounting a productive innate immune response
post-transplantation. When syngeneic BMT is performed, this system allows the study of
BMT-induced alterations in innate immune cell function that are independent of the con-
founding effects of immunosuppressive therapy and graft-versus-host disease. Studies
from several laboratories, including our own show that pulmonary susceptibility to bacte-
rial infections post-BMT are largely due to alterations in the lung alveolar macrophages.
Changes in these cells post-BMT include cytokine and eicosanoid dysregulations, scav-
enger receptor alterations, changes in micro RNA profiles, and alterations in intracellular
signaling molecules that limit bacterial phagocytosis and killing. The changes that occur
highlight mechanisms that promote susceptibility to infections commonly afflicting HSCT
recipients and provide insight into therapeutic targets that may improve patient outcomes
post-HSCT.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION OVERVIEW
Early observations made in the 1950s paved the way for the
development of hematopoietic stem cell transplantation (HSCT).
Lorenz (1951) showed that animals exposed to radiation could be
protected by infusion of bone marrow cells. These studies, together
with the previous observation that the deleterious effects of ion-
izing radiation could be prevented in mice by shielding organs
with lead, pushed transplantation forward as a possible ther-
apy for patients suffering from hematologic malignancies (Little
and Storb, 2002). HSCT is now used to treat a variety of disor-
ders, including malignant, congenital, and autoimmune disorders
(Cutler, 2005; Copelan, 2006).
Prior to receiving a graft, transplant recipients undergo con-
ditioning regimens that include total body irradiation (TBI),
chemotherapy, or a combination of TBI and chemotherapy
(Aschan, 2007; Passweg, 2012). These regimens subject the recip-
ients’ organs, including the lungs, to their cytotoxic effects. The
hope is to eradicate the malignant or autoimmune cells and replen-
ish the patient with healthy hematopoietic stem cells (HSCs). If
the intensity of the conditioning regimen is myeloablative, repop-
ulation of hematopoietic cells will predominantly come from the
donor HSCs (Tomita, 1994; Aschan, 2007). Non-myeloablative
conditioning, also known as reduced intensity conditioning (RIC)
will allow repopulation from both donor and host HSCs. Depend-
ing on the underlying disease, HSCT recipients receive self HSCs
(autologous) or HSCs from a human leukocyte antigen (HLA)-
matched, related, or unrelated donor (allogeneic). A recent study
analyzing the global use of transplantation reported that autol-
ogous HSCT continues to be more highly implemented than
allogeneic transplant (Gratwohl et al., 2010). Although autologous
transplant recipients are unlikely to suffer from graft-versus-host
disease (GvHD) which arises when the donor leukocytes mount
an immune response against different HLA antigens expressed
by the host, autologous transplants performed for hematologic
malignancies lack the beneficial effects of graft-versus-leukemia
(GvL). In the GvL reaction the allogeneic donor HSCs recognize
and remove leukemic cells within the host by virtue of the HLA
mismatches (Kolb, 2008).
Traditionally, HSCs were aspirated from the bone marrow of
donor patients and later infused into recipients. This procedure
was often painful for the donor. However, technical advances now
allow for mobilization of HSCs into the peripheral blood with the
use of the growth factor, granulocyte-colony stimulating factor
(G-CSF) (Cutler, 2005; Copelan, 2006). Treatment of donors with
G-CSF allows HSCs to be collected with a simple blood draw. Addi-
tionally, HSCs can also be harvested from umbilical cord blood
www.frontiersin.org May 2013 | Volume 4 | Article 126 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Domingo-Gonzalez and Moore Innate immune changes post-HSCT
(Tse, 2008; Peffault de Latour et al., 2013). Each of these tech-
niques has inherent advantages and disadvantages and have been
discussed elsewhere (Körbling and Anderlini, 2001; Copelan, 2006;
Tse, 2008). RIC has evolved as an alternative to the more traditional
myeloablative conditioning regimens for individuals that would
have otherwise been unable to undergo transplantation as a ther-
apy due to age, comorbidities, or disorders associated with high-
risk non-relapse mortality (Giralt, 2005). Interestingly, despite a
reduction in intensity regimens, recipients of RIC HSCT display
similar incidence of infectious complications and infection-related
mortality (Kim et al., 2013).
PULMONARY COMPLICATIONS
Although HSCT has become standard care for malignant and
non-malignant disorders, its success is significantly limited by
the different pulmonary complications that arise following trans-
plantation (Cordonnier, 1986; Griese, 2000; Roychowdhury, 2005;
Afessa and Peters, 2006; Copelan, 2006). The engraftment process
can be characterized by three distinct phases: the pre-engraftment
(0–30 days), early post-engraftment (30–100 days), and late post-
engraftment phases (beyond 100 days) (Afessa and Peters, 2006;
Wingard et al., 2010; Coomes et al., 2011). HSCT recipients are
more susceptible to infections prior to engraftment and early after
engraftment. During this early time period, the increased suscep-
tibility is mostly due to the incomplete recovery of the immune
cell compartment, and is often associated with decreased neu-
trophil numbers or function (Zimmerli et al., 1991). Although
engraftment indicates the transplant was successful in reconstitut-
ing hematopoietic cell populations, it is evident that this does not
correlate with recovery of an effective immune system, as patients
remain susceptible to diverse complications (including infections)
long after engraftment occurs (Soubani, 1996; Afessa and Peters,
2006; Coomes et al., 2011). Pulmonary complications, both infec-
tious and non-infectious, have been reported to affect up to 60%
of transplant recipients (Soubani, 1996; Copelan, 2006). Similarly,
autopsy studies performed on both allogeneic and autologous
transplant recipients revealed pulmonary complication rates of
80–89% (Roychowdhury, 2005). Although allogeneic transplants
have increased incidence of infectious pulmonary complications,
this may be attributed, in part, to the use of immunosuppressive
therapy required to prevent GvHD. Additionally, GvHD can cause
mucosal barrier disruptions which also increase susceptibility to
pathogens. Interestingly, however, autologous HSCT recipients
also continue to suffer from increased susceptibility to pulmonary
infections even though this form of transplant does not require
immunosuppressive therapies (Afessa et al., 2012). These observa-
tions highlight the inherent dysfunction of the immune response
following transplant and suggest that some degree of impaired
function is independent of the immunosuppressive therapies or
GvHD. The idea that alveolar macrophages (AMs) are inherently
less functional post-HSCT is supported by previous observations
that AMs obtained from pulmonary lavage of allogeneic HSCT
patients late in the post-engraftment phase were functionally
defective even in the absence of overt pulmonary infection (Win-
ston et al., 1982). Defects noted in the AMs from these patients
included defects in chemotaxis, phagocytosis, and killing of Can-
dida pseudotropicalis as well as phagocytosis and killing of bacteria
including Staphylococcus aureus and Listeria monocytogenes. This
same study suggested that the defects may be primarily confined
to the lung as the function of peripheral blood monocytes in
these same assays was similar to control patients (Winston et al.,
1982).
Non-infectious complications that arise following transplant
include peri-engraftment respiratory distress syndrome (PERDS),
diffuse alveolar hemorrhage (DAH), idiopathic pneumonia syn-
drome (IPS), and bronchiolitis obliterans syndrome (BOS)
(Soubani, 1996; Afessa, 2001; Roychowdhury, 2005; Afessa and
Peters, 2006; Soubani and Uberti, 2007; Afessa et al., 2012). These
occur throughout the different engraftment phases but BOS in par-
ticular, is more commonly seen late post-engraftment (Soubani
and Uberti, 2007). Malignant relapse or secondary malignancy
also complicate successful transplants (Copelan, 2006; Roziakova,
2011). Many times the non-infectious complications can mani-
fest in conjunction with infectious complications (Metcalf et al.,
1994; Roychowdhury, 2005). Additionally, infections are risk fac-
tors for development of some forms of non-infectious lung injury
which may occur later, such as IPS (Versluys, 2010). Importantly,
infections with bacterial, viral, and fungal pathogens can afflict
both allogeneic and autologous HSCT recipients at multiple times
post-transplant (Afessa and Peters, 2006; Lim, 2006).
Viral infections are common in HSCT patients. Cytomegalovirus
(CMV) infections predominate in the late phase of engraftment
and are associated with increased mortality (Boeckh, 2003, 2011;
Kotloff et al., 2004). The advent of prophylactic and antiviral ther-
apy usage has proven to be beneficial in limiting infection in HSCT
patients; however, CMV can be particularly difficult to detect and
treat (Boeckh, 2011). One autopsy study revealed that 65% of
CMV infections were not diagnosed ante mortem, thus highlight-
ing the frequency of missed detection (Chandrasekar, 1995). Thus,
HSCT patients are highly susceptible to CMV as well as other her-
pesviruses (Soubani et al., 1996; Ljungman, 2002; Marr, 2012).
Fungal pathogens are one of the major causes of significant mor-
bidity and mortality in HSCT recipients (Marr et al., 2002). Prior
to the use of azole-based anti-fungal prophylaxis, Candida spp.
were the leading fungal pathogen following HSCT (Asano-Mori,
2010). However, following implementation of this anti-fungal
prophylactic treatment, Aspergillus spp. have become the predom-
inant fungal pathogen causing invasive fungal infections in the
lung of both autologous and allogeneic HSCT populations (Bow,
2009; Asano-Mori, 2010). When considering bacterial infections,
a shorter time to engraftment and the use of broad-spectrum
antibiotics have improved the incidence of bacterial infections,
specifically Gram-negative bacteria (Cruciani, 1996; Therriault,
2010). However, bacterial pneumonias remain a significant cause
of mortality in this immunocompromised population (Therri-
ault, 2010; Marr,2012). Pseudomonas aeruginosa (a Gram-negative
bacteria) is the most common pathogen isolated within 100 days
post-engraftment and is associated with high recurrence rates due
to increasing antibiotic resistance (Hakki et al., 2007). Streptococ-
cus pneumoniae is the leading Gram-positive bacterial infection
in HSCT recipients, and together with another Gram-positive
agent, S. aureus, afflicts patients in the late post-engraftment
phase and causes significant mortality (Chen et al., 2003; Marr,
2012).
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ANIMAL MODELING
Murine bone marrow transplant (BMT) models for both syn-
geneic (genetically identical donor) and allogeneic (non-identical)
transplantation offer the opportunity to study changes in the pul-
monary immune system and microenvironment following trans-
plantation. In these systems, donor cells are harvested from the
femur and tibia of genetically inbred mice and introduced into
lethally irradiated syngeneic or allogeneic mice to reconstitute
ablated hematopoietic compartments. In order to force recon-
stitution of myeloid cells from hematopoietic donors, myeloab-
lative conditioning is employed. This can be done via TBI or via
chemotherapy regimens. One note of caution however, is that dif-
ferent strains of mice have differing susceptibilities to TBI dosage.
For instance, in our laboratory we routinely use 13 Gy split dose
of TBI to myeloablate C57Bl/6 mice and only 10 Gy for the same
purpose in Balb/c mice. Addition of splenic T cells along with
the donor bone marrow inoculum can hasten reconstitution in
syngeneic transplants (Ojielo et al., 2003) and can be a source of
alloreactive T cells in models of allogenic BMT hoping to study
GvHD or graft versus leukemia responses ( Reddy et al., 2005; Kato
et al., 2010).
Studies comparing conditioning regimens for their ability to
reconstitute AMs in recipient syngeneic BMT mice showed that
both dual-chemotherapy regimens (4 days of 25 mg/kg busulfan
followed by 2 days of 100 mg/kg cyclophosphamide) and 13 Gy
TBI regimens induced greater than 50% reconstitution of AMs
and spleen cells from donor stem cells by week 5 post-BMT
(Hubbard et al., 2008). Thirteen Gray TBI, when compared to
dual-chemotherapy, was the more effective conditioning regimen.
With 13 Gy TBI conditioning, donor reconstitution, measured
by the percentage of CD45.1 donor cells in CD45.2 recipient
mice, was observed at 82± 2% in AMs and 95± 1% in spleen
cells (Hubbard et al., 2008). The percentages of donor-derived
AMs and spleen cells with dual-chemotherapy were 56± 6.2
and 72.3± 2.1% (Hubbard et al., 2008). Similar defects in host
immune responses were noted in all of these myeloablative con-
ditioning regimens regardless of whether T cells were included in
the original inoculum (Hubbard et al., 2008).
DEFECTIVE PULMONARY INNATE IMMUNITY TO BACTERIA
BACTERIAL INFECTION MODEL
Despite the use of antibiotic prophylaxis, infectious pulmonary
complications continue to afflict both autologous and allogeneic
HSCT recipients throughout the process of engraftment and well
into the late post-engraftment phase (>100 days) (Chen et al.,
2003; Marr, 2012). Although reported to predominantly mani-
fest in the pre-engraftment and early post-engraftment phases, P.
aeruginosa-driven pneumonia is also seen in some cases more than
a year post-initial transplant (Chen et al., 2003). To understand
how alterations following transplantation enhance susceptibility
of HSCT patients to bacterial infections, we exposed syngeneic
BMT mice to a sublethal dose of P. aeruginosa (PAO1 strain;
5× 105 CFU) (Ojielo et al., 2003; Ballinger et al., 2006a, 2008;
Coomes et al., 2011) or S. aureus (USA300 stain; 7× 107 CFU)
via intratracheal (i.t.) injection. Twenty-four hours post-infection,
lungs and blood are collected to determine bacterial burden.
Using this model, we found that syngeneic BMT mice are more
susceptible to bacterial infections as they are unable to effectively
clear P. aeruginosa (Ojielo et al., 2003; Ballinger et al., 2006a, 2008;
Coomes et al., 2011; Domingo-Gonzalez et al., 2013) or S. aureus
(Domingo-Gonzalez et al., 2013) from the lung and contain higher
levels of bacterial dissemination compared to untransplanted,
infected control mice. The remainder of this review will highlight
the pathologic abnormalities which we have characterized in the
innate immune cells using this model system. It should be noted
that we utilized mice at week 5 post-BMT when hematopoietic
reconstitution (including AMs) from donor HSCs was maximal
(Hubbard et al., 2008). We assessed bacterial clearance 24 h post-
infection and we used specific pathogen free mice; thus, there was
little chance of co-infection. Using this model system, we have
identified numerous BMT-induced changes that characterize the
AMs and polymorphonuclear leukocytes (PMNs) that repopulate
the host.
CYTOKINE AND EICOSANOID DYSREGULATION POST-BMT
In humans, bacterial infection is commonly seen in the neu-
tropenic phase due to a slow or incomplete engraftment, or
the use of immunosuppressive therapy (Afessa and Peters, 2006;
Coomes et al., 2011). However, in our syngeneic BMT model,
there was prolonged susceptibility to bacterial infection even after
full hematopoietic engraftment had occurred. These observations
suggested that the environment of the lung post-BMT may be
suppressing the function of the innate immune cells which had
repopulated the alveolar space. These studies revealed that syn-
geneic BMT mice are unable to successfully induce TNFα or IFNγ
in the lung following infection with P. aeruginosa (Ojielo et al.,
2003). TNFα in particular, has been shown to be especially impor-
tant in controlling a P. aeruginosa infection (Sapru et al., 1999;
Chen et al., 2000). Balb/c mice are naturally resistant to P. aerug-
inosa and have been shown to produce higher levels of TNFα in
the lung following infection while the susceptible C57Bl/6 strain
produces significantly lower levels of TNFα post-infection (Gos-
selin, 1995; Morissette et al., 1995). Interestingly, in vivo treatment
of Balb/c mice with an anti-murine TNFα monoclonal antibody
reversed resistance to infection and the anti-TNFα-treated mice
exhibited higher bacterial loads in the lung (Gosselin, 1995). Sim-
ilarly, a separate study showed that TNFα-knockout mice suffered
from significantly higher bacterial burden in the lungs following
challenge with P. aeruginosa compared to their TNFα-sufficient
wild-type controls (Yu, 2000). These data highlight the impor-
tance of TNFα in mediating clearance of P. aeruginosa and suggest
that loss of the mediator post-BMT likely contributes to impaired
clearance of this pathogen.
In addition to TNFα, IFNγ is also important for the acti-
vation of macrophages. IFNγ functions to prime macrophages
to undergo classical activation but does not alone activate
macrophages (Nathan, 1991; Mosser, 2003). It requires a second
signal, provided by either exogenous TNFα or Toll-like receptor
(TLR)-induced TNFα (57). However, as both IFNγ and TNFα
were decreased in the alveolar space and TNFα production was
decreased by AMs following BMT in response to i.t. challenge
with P. aeruginosa, it is possible that the lack of activation signals
for macrophages contribute to the inability to control and clear
bacterial insult (Ojielo et al., 2003).
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Eicosanoids derive from arachidonic acid and are lipid medi-
ators produced by different cell types, including alveolar epithe-
lial cells (AECs), AMs, and PMNs (Ballinger et al., 2006a, 2007;
Folco and Murphy, 2006). Prostaglandins and leukotrienes are
end-products of arachidonic acid metabolism via the cyclooxyge-
nase (COX) and 5-lipoxygenase enzymatic pathways, respectively
(Folco and Murphy, 2006). These eicosanoids have diverse effects
on cells. Leukotrienes (LTB4 and cysteinyl leukotrienes or cys LTs)
seem to have an overall pro-inflammatory effect on innate immune
cells as they have been shown to promote bacterial phagocytosis
and killing in both AMs and PMNs (Bailie, 1996; Mancuso et al.,
1998; Mancuso, 2001; Serezani et al., 2005). Similarly, cys LTs have
been shown to be involved in the induction of TNFα production
by both AMs and recruited PMNs (Sayers, 1988; Ménard, 2000).
Studies on the effects of prostaglandins, particularly prostaglandin
E2 (PGE2), however, suggest they may negatively regulate innate
immune responses (Aronoff et al., 2004). PGE2 signals through
four distinct G protein-coupled seven transmembrane spanning
E prostanoid (EP) receptors (Funk, 2001; Hubbard et al., 2001).
The inhibitory effects of PGE2 have been attributed to binding
of EP2 and EP4. Stimulation of the EP2 or EP4 receptors results
in the induction of intracellular cyclic adenosine monophosphate
(cAMP) and activation of the downstream cAMP targets: pro-
tein kinase A (PKA) and the exchange protein activated by cAMP
(Epac-1) (Aronoff et al., 2004, 2005). Activation of PKA and/or
Epac-1 has been shown to impair both AM and PMN function
as well as inhibit the production of pro-inflammatory mediators,
leukotrienes, and reactive oxygen species (He, 2001; Aronoff et al.,
2005). Interestingly, PGE2 has also been shown to induce IL-10,
an immunosuppressive cytokine (Harizi, 2002; MacKenzie et al.,
2012).
Prostaglandin E2 has been reported to be elevated in the serum
of autologous HSCT recipients (Cayeux et al., 1993). This increase
in PGE2 was not specific to a particular conditioning regimen
indicating that all HSCT patients are susceptible to overproduc-
tion of PGE2 (Cayeux et al., 1993). We have previously reported
that PGE2 is elevated in the lungs of mice following syngenic BMT
(Ballinger et al., 2006a). This overproduction was localized to AMs,
recruited PMNs, and structural cells, whereas cys LTs are decreased
in BMT AMs (Ballinger et al., 2006a). The increased production
of PGE2 is likely to be systemic as BMT peritoneal lavage fluid also
displayed higher PGE2 levels (Ballinger et al., 2006a). Although
it is tempting to suspect PGE2-induced IL-10 expression may be
responsible for the impaired immune environment post-BMT, IL-
10 was decreased in the BMT lung following infectious stimuli
indicating that the inhibitory effects of PGE2 were likely inde-
pendent of the immunosuppressive effects of IL-10 (Ojielo et al.,
2003). Interestingly, pharmacological inhibition of the COX path-
way post-BMT limited PGE2 production and restored cysLT levels
in AMs indicating that PGE2 negatively regulates cysLTs in the set-
ting of BMT (Ballinger et al., 2006a). The importance of cysLTs in
supporting the clearance and resolution of pulmonary infections
post-BMT is observed in mice that received HSCs from granu-
locyte macrophage colony stimulating factor (GM-CSF)−/− mice
(Ballinger et al., 2008). GM-CSF−/− BMT mice are defective in
cysLT production post-infection and are more susceptible to P.
aeruginosa infection.
Granulocyte macrophage colony stimulating factor is an
important cytokine for regulating innate immune cells, par-
ticularly macrophages. Previous studies have shown that GM-
CSF is required for effective clearance of P. aeruginosa even in
untransplanted mice (Ballinger et al., 2006b). Untransplanted
GM-CSF−/− mice had increased bacterial burden compared to
wild-type controls. However, the source and amount of GM-CSF
is critical to determining host defense function post-BMT. AMs
from wild-type syngeneic BMT mice show an overproduction of
GM-CSF post-BMT. Interestingly, in human HSCT literature, ele-
vated production of GM-CSF by AMs during the pancytopenia
period was also noted (Whittle et al., 2001). While we initially
thought excess AM-derived GM-CSF would be beneficial, this was
not the case because the excess GM-CSF in AMs post-BMT drove
upregulation of the EP2 receptor on AMs (Ballinger et al., 2008).
The inhibitory effects of PGE2 signaling via upregulated EP2 in
the wild-type BMT mice impaired bacterial phagocytosis and
killing as well as cys LT and TNFα production. When GM-CSF−/−
HSCs were used to repopulate WT mice, host defense improved
(Ballinger et al., 2008). Without AM-derived GM-CSF post-BMT,
EP2 receptors were not elevated and mice showed improved host
defense despite the fact that PGE2 levels were still elevated post-
BMT. In the absence of EP2 elevations, the GM-CSF−/− BMT
mice retained production of cys LTs and TNFα. It is important to
stress that improved host defense was only seen in the situation
where GM-CSF production was blocked in hematopoietic cells
post-transplant. When WT HSCs were transplanted into GM-
CSF−/− mice, host defense was once again impaired (Ballinger
et al., 2008). These data highlight the importance of cross-talk
between AECs and AMs post-BMT. AEC-derived GM-CSF is ben-
eficial post-BMT whereas AM-derived GM-CSF is detrimental.
In the human HSCT literature mentioned above, elevations of
AM-derived GM-CSF in human allogenic HSCT recipients pre-
dicted development of later lung disease (Whittle et al., 2001).
This complex homeostatic regulation of GM-CSF means block-
ing this cytokine needs to be targeted specifically to the AMs to
be beneficial. Newer approaches to create microparticle delivery
vesicles that are readily uptaken by phagocytes, but not structural
cells may offer a way to deliver Ab or siRNA-based anti-GM-CSF
therapies in the future (Jhunjhunwala and Little, 2011).
CELLULAR ALTERATIONS
Alveolar macrophages
Induction of PGE2 via cyclooxygenase-2 demethylation. Alveo-
lar macrophages compose 95% of all leukocytes in the airspaces
and thus, are the sentinel phagocytic cells in the lungs (Gordon and
Read, 2002; Martin and Frevert, 2005). They have been implicated
as critical innate immune cells for clearance of bacteria as deple-
tion of AMs through clodronate liposomes resulted in impaired
host defense against P. aeruginosa (Kooguchi et al., 1998). As AMs
are key players in a productive innate immune response in the
lungs, their function following transplantation is essential. How-
ever, data suggest that BMT AMs demonstrate altered cytokine
and eicosanoid production which impair their innate immune
function and predispose the host to infections post-BMT.
Prostaglandin E2 is significantly overproduced by BMT AMs
(Ballinger et al., 2006a). The cause for elevated basal levels of PGE2
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in the AMs post-BMT may be multifactorial. It is possible that
differences in differentiation of AMs from donor-derived HSCs
versus a resident AM stem cell may influence the amount of PGE2
observed after transplant (Tarling et al., 1987). However, studies
indicate that this cannot fully explain the defect since mice receiv-
ing a lower dose of irradiation (8 Gy) contain a large percentage
of host-derived AMs (∼36%) that also overproduce PGE2 post-
transplant, albeit at approximately a threefold lower level than seen
in AMs derived from donor HSCs (Hubbard et al., 2008). To fur-
ther understand how PGE2 might be overproduced post-BMT,
upstream regulators of PGE2 in the arachidonic acid metabo-
lism cascade were analyzed. COX-2, the inducible form of COX,
processes arachidonic acid to present to prostaglandin synthase
enzymes to form prostaglandins (Funk, 2001). COX-2 expres-
sion is also increased following BMT (Domingo-Gonzalez, 2012).
This increase in expression was due to significant hypomethy-
lation of the COX-2 gene post-transplant. This demethylation
induced expression of COX-2 and thus allowed increased PGE2
synthesis in the setting of BMT. The demethylation of the COX-2
gene was shown to be regulated at least in part via the actions of
transforming growth factor beta (TGFβ), another cytokine that
is elevated in the lungs post-BMT and is produced by the AECs
(Domingo-Gonzalez, 2012). To determine the effects of TGFβ on
COX-2 expression in BMT AMs, mice containing a dominant neg-
ative TGFβRII expressed under the CD11c promoter were used
as donor mice (Domingo-Gonzalez, 2012). Thus, in these trans-
plants, AMs would be insensitive to TGFβ signaling. These studies
revealed that blocking TGFβ signaling restored methylation pat-
terns within the COX-2 gene. Taken together, these studies indicate
that elevations of TGFβ post-BMT induce COX-2 expression via
demethylation of the gene (Domingo-Gonzalez, 2012). While not
the subject of this review, it is interesting to note that elevations
of TGFβ post-BMT also impair effector T cell responses and this
alteration increases the susceptibility of BMT mice to herpesviral
infections as well (Coomes et al., 2010, 2011).
Alveolar macrophages have been reported to exhibit decreased
ability to phagocytose and kill bacteria following allogeneic HSCT
(Winston et al., 1982). As AMs are important first responders to
infection in the lung, their function is essential for preventing
bacterial dissemination as well as promoting bacterial clearance
by engulfment and removal of infectious pathogens, and also by
releasing chemokines to stimulate the recruitment and activation
of immune cells (Martin and Frevert, 2005). Murine BMT AMs
display an impaired ability to phagocytose and kill P. aeruginosa
(Ojielo et al., 2003; Ballinger et al., 2006a; Hubbard et al., 2010,
2011). This defect has been shown to be dependent on PGE2 sig-
naling as pharmacological inhibition of the COX pathway through
the use of indomethacin can restore a productive host defense
against bacteria both in vitro and in vivo post-BMT. Furthermore,
blocking the EP2 receptor (using AH 6809 a strong EP2 antagonist
with weaker activity at the EP1 and DP1 receptors) in BMT AMs
inhibits PGE2 signaling and restores phagocytosis of P. aeruginosa
(Ballinger et al., 2006a). Thus, the next experiments discussed
were undertaken to determine how PGE2 signaling inhibits AM
phagocytosis and bacterial killing post-BMT.
Phosphatase and tensin homolog deleted on chromosome 10
(PTEN) elevations. Endocytosis of pathogens can occur in a
number of ways with two major ways being through opsonized and
non-opsonized phagocytosis. As bacterial uptake is impaired post-
BMT, we sought to better understand the reasons for this. PTEN
functions to dephosphorylate both protein and lipid targets, and
has been traditionally known for its effects on PI3K/AKT signal-
ing through dephosphorylation of phosphatidylinositol (Cutler,
2005; Copelan, 2006; Passweg, 2012)-triphosphate (PIP3) (Gunzl
and Schabbauer, 2008). Previous studies have shown that PGE2-
induced PTEN activity can inhibit FcγR-mediated phagocytosis
and PI3K/AKT activation (Canetti et al., 2007). In the syngeneic
BMT model, overproduction of PGE2 stimulates increased PTEN
activity, resulting in decreased serum-opsonized phagocytosis
(Hubbard et al., 2011). Using myeloid-specific PTEN conditional
knockout (PTEN CKO) mice as BMT donors, recipient mice had
improved, but not completely restored, host defense to in vivo bac-
terial challenge. This rescued response correlated with recovered
serum-opsonized phagocytosis by AMs and improved killing of P.
aeruginosa by both AMs and PMNs. Interestingly, non-opsonized
phagocytosis in AMs was only partially recovered (Hubbard et al.,
2011). This partial restoration may be due to persisted elevation
of the IL-1 receptor-associated kinase-M (IRAK-M) post-BMT.
IRAK-M elevations. A member of the IRAK family of ser-
ine/threonine kinases, IRAK-M functions as a negative regula-
tor of MyD88-dependent TLR signaling (Kobayashi, 2002). Our
BMT model revealed that PGE2 can upregulate IRAK-M in AMs
(Hubbard et al., 2010). Furthermore, BMT mice receiving genet-
ically ablated IRAK-M−/− donor HSCs were able to control and
clear the bacterial infection similarly to untransplanted controls.
This recovery also correlated with rescued TNFα, cys LTs, and
AM function (including non-opsonized phagocytosis and killing)
(Hubbard et al., 2010). Interestingly, these mice retained overpro-
duction of PGE2 and overexpression of the inhibitory receptor,
EP2. Thus, these data suggest that the inhibitory effects of PGE2
are dependent on IRAK-M and that IRAK-M is a critical down-
stream mediator of inhibitory PGE2 signaling (Hubbard et al.,
2010). Taken together, these studies suggest that PGE2 signals
through IRAK-M independently of PTEN and increased activity
of IRAK-M and PTEN promote differential effects on opsonized
and non-opsonized phagocytosis. Furthermore, the PTEN CKO
studies highlight the importance of non-opsonized phagocytic
responses in the lung following transplant, as complete recovery of
serum-opsonized phagocytosis and bacterial killing did not com-
pletely abrogate in vivo susceptibility measured 24 h post-infection
(Hubbard et al., 2011).
Scavenger receptor alterations. Non-opsonized phagocytosis is
primarily mediated by scavenger receptors (SRs), specifically Class
A SRs (Palecanda and Kobzik, 2001). Within this family of SRs
are SR-AI and II, macrophage receptor with a collagenous struc-
ture (MARCO), SR with C-type lectin (SRCL), and SR recep-
tor A5 (SCARA5) (Peiser et al., 2002). SR-AI and II are splice
variants, and together with MARCO, have been associated with
mediating non-opsonized phagocytosis in macrophages (Peiser
et al., 2002). Their importance in bacterial clearance is highlighted
by the susceptibility of individual MARCO−/− and SR-AI/II−/−
mice to S. pneumoniae (Arredouani et al., 2004, 2006). Defec-
tive phagocytosis of S. pneumoniae in SR-AI/II−/− mice has also
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been reported (Arredouani et al., 2006). Interestingly, the impaired
phagocytosis of non-opsonized P. aeruginosa in our BMT model
correlated with aberrant SR profiles (decreased MARCO and
increased SR-AI/II expression) (Domingo-Gonzalez et al., 2013).
Treatment of untransplanted AMs with soluble MARCO, inhib-
ited phagocytosis similarly to pan class A SR inhibitors and was
comparable to the level of phagocytosis noted against P. aerugi-
nosa in wild-type BMT AMs. In contrast, SR-AI/II overexpression
explained the surprising enhancement of S. aureus phagocytosis
by BMT AMs (Domingo-Gonzalez et al., 2013).
The differences in SR profiles observed following transplant can
be attributed to PGE2. Exogenous treatment of naïve AMs with
PGE2 decreased MARCO and increased SR-AI/II considerably
(Domingo-Gonzalez et al., 2013). The mechanism(s) explaining
how PGE2 is able to regulate SR expression is not fully character-
ized. However, our studies revealed that PGE2 can inhibit expres-
sion of microRNA-155 (miR-155) (Domingo-Gonzalez et al.,
2013). MicroRNAs are small non-coding RNAs that typically tar-
get 3′untranslated regions (3′UTR) and can inhibit or stabilize
mRNA expression or in many cases inhibit mRNA translation
(He and Hannon, 2004; Chen and Rajewsky, 2007). miR-155 has
been generally shown to play a role in promoting an inflammatory
response as it has been shown to stabilize TNFα mRNA and thus
promote expression (Bala et al., 1436). In the context of transplant,
miR-155 expression is decreased by PGE2 (Domingo-Gonzalez
et al., 2013). Interestingly, the 3′UTR of SR-AI/II contains a puta-
tive miR-155 target sequence (TargetScan). Blocking miR-155 can
induce expression of SR-AI/II and result in enhanced phagocytosis
of S. aureus (Domingo-Gonzalez et al., 2013). These results sug-
gest that by negatively regulating an inhibitor of SR-AI/II, PGE2
can indirectly induce expression of this SR. The mechanism for
how PGE2 reduces MARCO expression is unknown at present,
but does not involve miR-155. Importantly, despite differences
in levels of phagocytosis of P. aeruginosa and S. aureus, a defect
in killing remains in BMT AMs which ultimately confers sus-
ceptibility to both bacterial infections (Domingo-Gonzalez et al.,
2013). As mentioned above, this killing defect may relate to both
IRAK-M elevation and PTEN activation post-BMT. Loss of miR-
155 in response to PGE2 signaling may also serve to destabilize
TNFα mRNA post-BMT, and this is also likely to impair bacterial
killing.
Lung epithelial cells
Alveolar epithelial cells are the structural cells lining the alveo-
lus. Type II AECs are important secretors of pulmonary surfac-
tant, are progenitors to type I AECs which line the majority of
the lung, and act as immunomodulators via interactions with
immune cells. Exposure to ionizing radiation induces damage to
the alveolar epithelial barrier causing changes in gene expression,
particularly cytokine expression (Rubin et al., 1995). We have pre-
viously shown that upon transplantation, AECs from BMT mice
are negatively affected by the transplant process. Specifically, AECs
overproduce PGE2 as well as TGFβ which as discussed above
inhibits AM function (Ballinger et al., 2006a; Coomes et al., 2010;
Domingo-Gonzalez, 2012). Furthermore, AECs are defective in
the synthesis of GM-CSF (Ballinger et al., 2006b, 2008) which
as discussed above is important for modulating AM function.
Another important defect that has been described post-BMT is
the loss of surfactant protein A (SPA) which is predominantly
synthesized by AECs (Yang, 2000; Wright, 2005). As SPA can
serve as a collectin (Wright, 2005) which can bind pathogens to
help facilitate phagocytosis via the SR-AI/II receptor (Kuronuma,
2004), loss of SPA post-BMT may be another reason why host
defense is impaired in the setting of HSCT. The fact that SPA
can bind to SR-AI/II (the receptor that is retained on BMT AMs)
may suggest that exogenous SPA therapy could prove beneficial
post-HSCT.
Polymorphonuclear leukocytes
A major role for PMNs lies in their ability to be recruited to the
lung upon inflammation or infection and assist in the killing
and ultimate clearance of pathogens (Wang, 2004; Koh, 2009).
Several studies have looked at the function of human PMNs
post-autologous HSCT (reviewed in Ramaprasad et al., 2010).
These human studies noted decreased respiratory burst, decreased
phagocytosis of C. albicans and decreased killing of S. aureus
(Gadish et al., 1991). Interestingly the role of GM-CSF in restor-
ing PMN function is mixed (Peters et al., 1988; Gadish et al., 1991;
Wiltschke et al., 1995).
In the context of murine syngeneic BMT, PMNs were shown to
have intact phagocytic ability but were defective in their ability to
kill the engulfed bacteria (Ballinger et al., 2006a). Genetic ablation
of GM-CSF in donor marrow improved, but did not fully restore,
PMN killing of P. aeruginosa (Ballinger et al., 2008).
PTEN-deficient neutrophils have been reported to exhibit
enhanced host immune responses (Subramanian et al., 2007; Li
et al., 2009). Previous studies had shown that alleviating the
repressive effect of PTEN on neutrophils, augmented neutrophil
chemotaxis (Subramanian et al., 2007). Similar to these studies,
our PTEN CKO BMT mice had elevated basal levels of PMNs in the
alveolar space compared to untransplanted wild-type controls and
recovered their ability to kill intracellular bacteria (Hubbard et al.,
2011). However, despite a rescued PMN phenotype, PTEN CKO
BMT mice were still susceptible to acute P. aeruginosa infection,
highlighting the importance AM function, specifically the need for
non-opsonized phagocytosis, post-BMT.
Table 1 | Summary of observed cellular alterations following syn-BMT.
AECs AMs PMNs
Cytokines (baseline
and post-infection)
↑TGFβ, PGE2,
↓GM-CSF
↑GM-CSF, PGE2,
↓cysLTs, TNFα
↑PGE2
Function ↓Phagocytosis,
bacterial killing
↓Bacterial killing
Intracellular
signaling
↑PTEN, IRAK-M Loss of PTEN
improves function,
IRAK-M levels do
not change
miRNA ↓miR-155
Scavenger
receptors
↑SR-AI/II,
↓MARCO
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FIGURE 1 | Alterations in innate immunity post-BMT. AEC production
of TGFβ and PGE2 are increased following transplant and both affect AM
function. AEC production of GM-CSF is reduced. TGFβ signaling in AMs
helps demethylate the COX-2 promoter to increase AM-derived PGE2
secretion. Overproduction of GM-CSF in AMs post-BMT leads to elevation
of the EP2 receptor. In response to PGE2 stimulation of increased EP2
receptors, AM phagocytosis of both opsonized and unopsonized
pathogens is impaired. This impaired phagocytosis is related to a loss of
MARCO expression as well as an upregulation of IRAK-M. Despite the fact
that PGE2 reduces miR-155 which leads to increased SR-AI/II expression,
bacterial killing in both AMs and PMNs is impaired. This is related to
activation of PTEN as well as increased IRAK-M. Not shown on the
diagram is the observation that TNFα expression in AMs is also lost as a
result of PGE2 signaling. We have demonstrated that these alterations
ultimately lead to impaired host defense against both Gram-negative P.
aeruginosa as well as Gram-positive S. aureus.
Together with AMs, the impaired function of PMNs can also
be attributed to elevated PGE2, as pharmacological inhibition of
PGE2 synthesis completely resolved their defect (Ballinger et al.,
2006a). Unlike BMT AMs, PMNs do not exhibit a phagocytic
defect and IRAK-M is not elevated in recruited PMNs. Thus, it
is likely that PGE2 is mediating impaired killing through PTEN,
as we have previously shown that PGE2 can induce PTEN activity
(Hubbard et al., 2011).
CONCLUSION
The cumulative data from our studies of murine syngeneic BMT
is summarized in Table 1 and suggests that the susceptibility to
pulmonary infections following HSCT is related to the prolonged
impairment of immune function, particularly of AMs and PMNs,
as well as cytokine alterations by AECs. The master innate immune
inhibitory mediator post-BMT appears to be PGE2. Defects of AM
phagocytosis and killing as well as defects in PMN killing limit
the ability of the host to fight off bacterial infections post-HSCT.
Blockade of PGE2 signaling or production can restore innate
immune function. Work using this BMT mouse model provides
critical insight into the causes of defective pulmonary immunity
observed in the setting of transplantation and in the absence of
immunosuppressive therapy or the confounding effects of GvHD.
Changes that characterize BMT AMs are diverse. Figure 1 pro-
vides a schematic overview of the changes that occur in AMs
following transplant. It is interesting that most of the changes
that occur can be attributed to eicosanoid dysregulation and the
enhanced signaling of PGE2 through overexpression of one of its
receptors, EP2. Signaling via EP2 regulates downstream targets;
IRAK-M is increased and PTEN is activated post-BMT. The end
result of these alterations is the impairment of AM and PMN
function. The use of general COX inhibitors (e.g., indomethacin
or aspirin) or COX-2-specific inhibitors (e.g., NS-398) may prove
beneficial to HSCT patients. More recently, the development of PF-
044148948, the first specific EP2 antagonist developed by Pfizer
(Wang, 2004) may offer the exciting advantage of blocking the
inhibitory effects of PGE2 signaling on AMs without shutting
down all prostaglandin production or effecting other EP recep-
tor signaling. Such a therapeutic may offer protection to HSCT
patients suffering from antibiotic resistant bacterial infections.
Finally, murine studies need to be confirmed in human HSCT
AMs. If elevations in COX-2 and EP2 signaling as well as loss
of SPA noted in murine studies can be verified in humans post-
HSCT, the next step will be to design clinical trials to test therapies
targeted at these transplant-induced alterations.
ACKNOWLEDGMENTS
This work was supported by NIH grants R56AI065543 and
T32AI007413, and a predoctoral fellowship from the American
Heart Association.
www.frontiersin.org May 2013 | Volume 4 | Article 126 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Domingo-Gonzalez and Moore Innate immune changes post-HSCT
REFERENCES
Afessa, B. (2001). Bronchiolitis
obliterans and other late onset
non-infectious pulmonary com-
plications in hematopoietic stem
cell transplantation. Bone Mar-
row Transplant. 28, 425–434.
doi:10.1038/sj.bmt.1703142
Afessa, B., Abdulai, R. M., Kre-
mers, W. K., Hogan, W. J., Lit-
zow, M. R., and Peters, S. G.
(2012). Risk factors and out-
come of pulmonary complications
after autologous hematopoietic stem
cell transplanthematopoietic stem
cell transplant complications. Chest
141, 442–450. doi:10.1378/chest.
10-2889
Afessa, B., and Peters, S. G. (2006).
Major complications follow-
ing hematopoietic stem cell
transplantation. Semin. Respir.
Crit. Care Med. 27, 297–309.
doi:10.1055/s-2006-945530
Aronoff, D. M., Canetti, C., and Peters-
Golden, M. (2004). Prostaglandin E2
inhibits alveolar macrophage phago-
cytosis through an E-prostanoid 2
receptor-mediated increase in intra-
cellular cyclic AMP. J. Immunol. 173,
559–565.
Aronoff, D. M., Canetti, C., Serezani, C.
H., Luo, M., and Peters-Golden, M.
(2005). Cutting edge: macrophage
inhibition by cyclic AMP (cAMP):
differential roles of protein kinase A
and exchange protein directly acti-
vated by cAMP-1. J. Immunol. 174,
595–599.
Arredouani, M., Yang, Z., Ning, Y.,
Qin, G., Soininen, R., Tryggvason,
K., et al. (2004). The scavenger
receptor MARCO is required for
lung defense against pneumococ-
cal pneumonia and inhaled par-
ticles. J. Exp. Med. 200, 267–272.
doi:10.1084/jem.20040731
Arredouani, M. S., Yang, Z., Imrich,
A., Ning, Y., Qin, G., and Kobzik,
L. (2006). The macrophage scav-
enger receptor SR-AI/II and
lung defense against pneumo-
cocci and particles. Am. J. Respir.
Cell Mol. Biol. 35, 474–478.
doi:10.1165/rcmb.2006-0128OC
Asano-Mori, Y. (2010). Fungal infec-
tions after hematopoietic stem cell
transplantation. Int. J. Hematol.
91, 576–587. doi:10.1007/s12185-
010-0574-0
Aschan, J. (2007). Risk assessment
in haematopoietic stem cell trans-
plantation: conditioning. Best Pract.
Res. Clin. Haematol. 20, 295–310.
doi:10.1016/j.beha.2006.09.004
Bailie, M. B. (1996). Leukotriene-
deficient mice manifest enhanced
lethality from Klebsiella pneumonia
in association with decreased
alveolar macrophage phagocytic
and bactericidal activities. J.
Immunol. 157, 5221–5224.
Bala, S., Marcos, M., Kodys,
K., Csak, T., Catalano, D.,
Mandrekar, P., et al. (1436).
Up-regulation of microRNA-
155 in macrophages contributes
to increased tumor necrosis
factor {alpha} (TNF{alpha}) pro-
duction via increased mRNA
half-life in alcoholic liver disease.
J. Biol. Chem. 286, 1436–1444.
doi:10.1074/jbc.M110.145870
Ballinger, M. N., Aronoff, D. M., McMil-
lan, T. R., Cooke, K. R., Okiewicz,
K., Toews, G. B., et al. (2006a). Crit-
ical role of prostaglandin E2 over-
production in impaired pulmonary
host response following bone mar-
row transplantation. J. Immunol.
177, 5499–5508.
Ballinger, M. N., Paine, R. III, Serezani,
C. H., Aronoff, D. M., Choi, E.
S., Standiford, T. J., et al. (2006b).
Role of granulocyte macrophage
colony-stimulating factor during
gram-negative lung infection with
Pseudomonas aeruginosa. Am. J.
Respir. Cell Mol. Biol. 34, 766–774.
doi:10.1165/rcmb.2005-0246OC
Ballinger, M. N., Hubbard, L. L.,
McMillan, T. R., Toews, G. B.,
Peters-Golden, M., Paine, R. III,
et al. (2008). Paradoxical role
of alveolar macrophage-derived
granulocyte-macrophage colony-
stimulating factor in pulmonary
host defense post-bone marrow
transplantation. Am. J. Physiol. Lung
Cell Mol. Physiol. 295, L114–L122.
doi:10.1152/ajplung.00309.2007
Ballinger, M. N., McMillan, T. R., and
Moore, B. B. (2007). Eicosanoid
regulation of pulmonary innate
immunity post-hematopoietic stem
cell transplantation. Arch. Immunol.
Ther. Exp. (Warsz.) 55, 1–12.
doi:10.1007/s00005-007-0001-2
Boeckh, M. (2003). Cytomegalovirus in
hematopoietic stem cell transplant
recipients: current status, known
challenges, and future strategies.
Biol. Blood Marrow Transplant.
9, 543–558. doi:10.1016/S1083-
8791(03)00287-8
Boeckh, M. (2011). Complications,
diagnosis, management, and preven-
tion of CMV infections: current and
future. Hematology Am. Soc. Hema-
tol. Educ. Program 2011, 305–309.
doi:10.1182/asheducation-
2011.1.305
Bow, E. J. (2009). Invasive fun-
gal infection in haematopoietic
stem cell transplant recipi-
ents: epidemiology from the
transplant physician’s viewpoint.
Mycopathologia 168, 283–297.
doi:10.1007/s11046-009-9196-6
Canetti, C., Serezani, C. H., Atrasz, R.
G., White, E. S., Aronoff, D. M.,
and Peters-Golden, M. (2007). Acti-
vation of phosphatase and tensin
homolog on chromosome 10 medi-
ates the inhibition of FcgammaR
phagocytosis by prostaglandin E2 in
alveolar macrophages. J. Immunol.
179, 8350–8356.
Cayeux, S. J., Beverly, P. C. L., Schulz,
R., and Dorken, B. (1993). Ele-
vated plasma prostaglandin E2 lev-
els found in 14 patients undergoing
autologous or stem cell transplan-
tation. Bone Marrow Transplant. 12,
603–608.
Chandrasekar, P. H. (1995). Autopsy-
identified infections among bone
marrow transplant recipients: a
clinico-pathologic study of 56
patients. Bone Marrow Transplanta-
tion Team. Bone Marrow Transplant.
16, 675–681.
Chen, C.-S., Boeckh, M., Seidel, K.,
Clark, J. G., Kansu, E., Madtes, D.
K., et al. (2003). Incidence, risk fac-
tors, and mortality from pneumo-
nia developing late after hematopoi-
etic stem cell transplantation. Bone
Marrow Transplant. 32, 515–522.
doi:10.1038/sj.bmt.1704162
Chen, G. H., Reddy, R. C., Newstead,
M. W., Tateda, K., Kyasapura, B.
L., and Standiford, T. J. (2000).
Intrapulmonary TNF gene therapy
reverses sepsis-induced suppression
of lung antibacterial host defense. J.
Immunol. 165, 6496–6503.
Chen, K., and Rajewsky, N. (2007).
The evolution of gene regulation by
transcription factors and microR-
NAs. Nat. Rev. Genet. 8, 93–103.
doi:10.1038/nrg1990
Coomes, S. M., Hubbard, L. L., and
Moore, B. B. (2011). Impaired
pulmonary immunity post-bone
marrow transplant. Immunol. Res.
50, 78–86. doi:10.1007/s12026-010-
8200-z
Coomes, S. M., Wilke, C. A., Moore,
T. A., and Moore, B. B. (2010).
Induction of TGF-beta 1, not
regulatory T cells, impairs antiviral
immunity in the lung follow-
ing bone marrow transplant.
J. Immunol. 184, 5130–5140.
doi:10.4049/jimmunol.0901871
Copelan, E. A. (2006). Hematopoi-
etic stem-cell transplantation. N.
Engl. J. Med. 354, 1813–1826.
doi:10.1056/NEJMra052638
Cordonnier, C. (1986). Pulmonary
complications occurring after
allogeneic bone marrow transplan-
tation. A study of 130 consecutive
transplanted patients. Cancer 58,
1047–1054. doi:10.1002/1097-
0142(19860901)58:5<1047::AID-
CNCR2820580512>3.0.CO;2-Y
Cruciani, M. (1996). Prophy-
laxis with fluoroquinolones
for bacterial infections in neu-
tropenic patients: a meta-analysis.
Clin. Infect. Dis. 23, 795–805.
doi:10.1093/clinids/23.4.795
Cutler, C. (2005). An overview of
hematopoietic stem cell transplanta-
tion. Clin. Chest Med. 26, 517–527.
doi:10.1016/j.ccm.2005.06.016
Domingo-Gonzalez, R. (2012). COX-2
expression is upregulated by DNA
hypomethylation after hematopoi-
etic stem cell transplantation.
J. Immunol. 189, 4528–4536.
doi:10.4049/jimmunol.1201116
Domingo-Gonzalez, R., Katz, S.,
Serezani, C., Moore, T., LeVine,
A., and Moore, B. (2013). PGE2-
induced changes in alveolar
macrophage scavenger recep-
tor profiles differentially alter
phagocytosis of P. aeruginosa
and S. aureus post-bone mar-
row transplant. J. Immunol.
doi:10.4049/jimmunol.1203274 (in
press)
Folco, G., and Murphy, R. C. (2006).
Eicosanoid transcellular biosynthe-
sis: from cell-cell interactions
to in vivo tissue responses.
Pharmacol. Rev. 58, 375–388.
doi:10.1124/pr.58.3.8
Funk, C. D. (2001). Prostaglandins and
leukotrienes: advances in eicosanoid
biology. Science 294, 1871–1875.
doi:10.1126/science.294.5548.1871
Gadish, M., Kletter, Y., Flidel, O.,
Nagler, A., Slavin, S., and Fabian,
I. (1991). Effects of recombi-
nant human granulocyte and
granulocyte-macrophage colony-
stimulating factors on neutrophil
function following autologous
bone marrow transplanta-
tion. Leuk. Res. 15, 1175–1182.
doi:10.1016/0145-2126(91)90187-X
Giralt, S. (2005). Reduced-intensity
conditioning regimens for hema-
tologic malignancies: what have
we learned over the last 10 years?
Hematology Am. Soc. Hematol.
Educ. Program 2005, 384–389.
doi:10.1182/asheducation-
2005.1.384
Gordon, S. B., and Read, R. C. (2002).
Macrophage defences against respi-
ratory tract infections. Br. Med. Bull.
61, 45–61. doi:10.1093/bmb/61.1.45
Gosselin, D. (1995). Role of tumor
necrosis factor alpha in innate resis-
tance to mouse pulmonary infection
with Pseudomonas aeruginosa. Infect.
Immun. 63, 3272–3278.
Frontiers in Immunology | Inflammation May 2013 | Volume 4 | Article 126 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Domingo-Gonzalez and Moore Innate immune changes post-HSCT
Gratwohl, A., Baldomero, H.,
Aljurf, M., Pasquini, M. C.,
Bouzas, L. F., Yoshimi, A., et al.
(2010). Hematopoietic stem cell
transplantation: a global per-
spective. JAMA 303, 1617–1624.
doi:10.1001/jama.2010.491
Griese, M. (2000). Pulmonary com-
plications after bone marrow
transplantation in children: twenty-
four years of experience in a single
pediatric center. Pediatr. Pulmonol.
30, 393–401. doi:10.1002/1099-
0496(200011)30:5<393::AID-
PPUL5>3.0.CO;2-W
Gunzl, P., and Schabbauer, G. (2008).
Recent advances in the genetic
analysis of PTEN and PI3K
innate immune properties.
Immunobiology 213, 759–765.
doi:10.1016/j.imbio.2008.07.028
Hakki, M., Limaye, A. P., Kim, H.
W., Kirby, K. A., Corey, L., and
Boeckh, M. (2007). Invasive
Pseudomonas aeruginosa infec-
tions: high rate of recurrence
and mortality after hematopoi-
etic cell transplantation. Bone
Marrow Transplant. 39, 687–693.
doi:10.1038/sj.bmt.1705653
Harizi, H. (2002). Cyclooxygenase-2-
issued prostaglandin e(2) enhances
the production of endogenous IL-
10, which down-regulates dendritic
cell functions. J. Immunol. 168,
2255–2263.
He, L., and Hannon, G. J. (2004).
MicroRNAs: small RNAs with
a big role in gene regulation.
Nat. Rev. Genet. 5, 522–531.
doi:10.1038/nrg1415
He, L. K. (2001). The expression
of cyclooxygenase and the pro-
duction of prostaglandin E2 in
neutrophils after burn injury and
infection. J. Burn Care Rehabil.
22, 58–64. doi:10.1097/00004630-
200101000-00012
Hubbard, L., Wilke, C., White, E., and
Moore, B. P. T. E. N. (2011). Lim-
its alveolar macrophage function
against Pseudomonas aeruginosa fol-
lowing bone marrow transplanta-
tion. Am. J. Respir. Cell Mol. Biol. 45,
1050–1058. doi:10.1165/rcmb.2011-
0079OC
Hubbard, L. L., Ballinger, M. N.,
Thomas, P. E., Wilke, C. A.,
Standiford, T. J., Kobayashi,
K. S., et al. (2010). A role
for IL-1 receptor-associated
kinase-M in prostaglandin E2-
induced immunosuppression
post-bone marrow transplanta-
tion. J. Immunol. 184, 6299–6308.
doi:10.4049/jimmunol.0902828
Hubbard, L. L., Ballinger, M. N.,
Wilke, C. A., and Moore, B. B.
(2008). Comparison of conditioning
regimens for alveolar macrophage
reconstitution and innate immune
function post bone marrow trans-
plant. Exp. Lung Res. 34, 263–275.
doi:10.1080/01902140802022518
Hubbard, N. E., Lee, S., Lim, D., and
Erickson, K. L. (2001). Differential
mRNA expression of prostaglandin
receptor subtypes in macrophage
activation. Prostaglandins Leukot.
Essent. Fatty Acids 65, 287–294.
doi:10.1054/plef.2001.0327
Jhunjhunwala, S., and Little, S. R.
(2011). Microparticulate systems for
targeted drug delivery to phagocytes.
Cell 10, 2047–2048.
Kato, K., Cui, S., Kuick, R., Mineishi,
S., Hexner, E., Ferrara, J. L., et
al. (2010). Identification of stem
cell transcriptional programs nor-
mally expressed in embryonic and
neural stem cells in alloreactive
CD8+ T cells mediating graft-
versus-host disease. Biol. Blood
Marrow Transplant. 16, 751–771.
doi:10.1016/j.bbmt.2010.01.012
Kim, S. H., Kee, S. Y., Lee, D. G., Choi,
S. M., Park, S. H., Kwon, J. C.,
et al. (2013). Infectious complica-
tions following allogeneic stem cell
transplantation: reduced-intensity
vs. myeloablative conditioning regi-
mens. Transpl. Infect. Dis. 15, 49–59.
doi:10.1111/tid.12003
Kobayashi, K. (2002). IRAK-M is a neg-
ative regulator of Toll-like receptor
signaling. Cell 110, 191–202. doi:10.
1016/S0092-8674(02)00827-9
Koh, A. Y. (2009). Inescapable need
for neutrophils as mediators of
cellular innate immunity to acute
Pseudomonas aeruginosa pneumo-
nia. Infect. Immun. 77, 5300–5310.
doi:10.1128/IAI.00501-09
Kolb, H.-J. (2008). Graft-versus-
leukemia effects of transplan-
tation and donor lympho-
cytes. Blood 112, 4371–4383.
doi:10.1182/blood-2008-03-077974
Kooguchi, K., Hashimoto, S., Kobayashi,
A., Kitamura, Y., Kudoh, I., Wiener-
Kronish, J., et al. (1998). Role
of alveolar macrophages in initi-
ation and regulation of inflam-
mation in Pseudomonas aerugi-
nosa pneumonia. Infect. Immun. 66,
3164–3169.
Körbling, M., and Anderlini, P.
(2001). Peripheral blood stem
cell versus bone marrow allo-
transplantation: does the source
of hematopoietic stem cells
matter? Blood 98, 2900–2908.
doi:10.1182/blood.V98.10.2900
Kotloff, R.,Ahya,V., and Crawford, S. W.
(2004). Pulmonary complications
of solid organ and hematopoietic
stem cell transplantation. Am. J.
Respir. Crit. Care Med. 170, 22–48.
doi:10.1164/rccm.200309-1322SO
Kuronuma, K. (2004). Pulmonary sur-
factant protein A augments the
phagocytosis of Streptococcus pneu-
moniae by alveolar macrophages
through a casein kinase 2-dependent
increase of cell surface localiza-
tion of scavenger receptor A. J.
Biol. Chem. 279, 21421–21430.
doi:10.1074/jbc.M312490200
Li, Y., Jia, Y., Pichavant, M., Loison,
F., Sarraj, B., Kasorn, A., et al.
(2009). Targeted deletion of tumor
suppressor PTEN augments neu-
trophil function and enhances host
defense in neutropenia-associated
pneumonia. Blood 113, 4930–4941.
doi:10.1182/blood-2008-06-161414
Lim, D. H. (2006). Pulmonary
complications after hematopoi-
etic stem cell transplantation. J.
Korean Med. Sci. 21, 406–411.
doi:10.3346/jkms.2006.21.3.406
Little, M.-T., and Storb, R. (2002).
History of haematopoietic stem-cell
transplantation. Nat. Rev. Cancer 2,
231–238. doi:10.1038/nrc748
Ljungman, P. (2002). Prevention
and treatment of viral infec-
tions in stem cell transplant
recipients. Br. J. Haematol.
118, 44–57. doi:10.1046/j.1365-
2141.2002.03515.x
Lorenz, E. (1951). Modification of
irradiation injury in mice and
guinea pigs by bone marrow injec-
tions. J. Natl. Cancer Inst. 12,
197–201.
MacKenzie, K. F., Clark, K., Naqvi, S.,
McGuire, V. A., Nöehren, G., Kris-
tariyanto, Y., et al. (2012). PGE2
induces macrophage IL-10 produc-
tion and a regulatory-like phenotype
via a protein kinase A–SIK–CRTC3
pathway. J. Immunol. 190, 565–577.
doi:10.4049/jimmunol.1202462
Mancuso, P. (2001). Leukotriene B4
augments neutrophil phagocy-
tosis of Klebsiella pneumoniae.
Infect. Immun. 69, 2011–2016.
doi:10.1128/IAI.69.4.2011-
2016.2001
Mancuso, P., Standiford, T. J., Mar-
shall, T., and Peters-Golden, M.
(1998). 5-Lipoxygenase reac-
tion products modulate alveolar
macrophage phagocytosis of Kleb-
siella pneumoniae. Infect. Immun.
66, 5140–5146.
Marr, K., Carter, R., Boeckh, M., Mar-
tin, P., and Corey, L. (2002). Inva-
sive aspergillosis in allogeneic stem
cell transplant recipients: changes in
epidemiology and risk factors. Blood
100, 4358–4366. doi:10.1182/blood-
2002-05-1496
Marr, K. A. (2012). Delayed opportunis-
tic infections in hematopoietic stem
cell transplantation patients:
a surmountable challenge.
Hematology Am. Soc. Hematol.
Educ. Program 2012, 265–270.
doi:10.1182/asheducation-
2012.1.265
Martin, T. R., and Frevert, C. W.
(2005). Innate immunity in the
lungs. Proc. Am. Thorac. Soc. 2,
403–411. doi:10.1513/pats.200508-
090JS
Ménard, G. (2000). Priming of alveolar
macrophages by leukotriene D(4):
potentiation of inflammation. Am.
J. Respir. Cell Mol. Biol. 23, 572–577.
doi:10.1165/ajrcmb.23.4.4152
Metcalf, J. P., Rennard, S. I., Reed,
E. C., Haire, W. D., Sisson, J. H.,
Walter, T., et al. (1994). Corticos-
teroids as adjunctive therapy for
diffuse alveolar hemorrhage associ-
ated with bone marrow transplan-
tation. Am. J. Med. 96, 327–334.
doi:10.1016/0002-9343(94)90062-0
Morissette, C., Skamene, E., and
Gervais, F. (1995). Endo-
bronchial inflammation following
Pseudomonas aeruginosa infection
in resistant and susceptible strains of
mice. Infect. Immun. 63, 1718–1724.
Mosser, D. M. (2003). The many
faces of macrophage activation.
J. Leukoc. Biol. 73, 209–212.
doi:10.1189/jlb.0602325
Nathan, C. (1991). Mechanisms and
modulation of macrophage acti-
vation. Behring Inst. Mitt. 88,
200–207.
Ojielo, C., Cooke, K. R., Mancuso, P.,
Standiford, T. J., Olkiewicz, K. M.,
Cloutheir, S., et al. (2003). Defec-
tive phagocytosis and clearance of
Pseudomonas aeruginosa in the lung
following bone marrow transplanta-
tion. J. Immunol. 171, 4416–4424.
Palecanda, A., and Kobzik, L. (2001).
Receptors for unopsonized
particles: the role of alveolar
macrophage scavenger recep-
tors. Curr. Mol. Med. 1, 589–595.
doi:10.2174/1566524013363384
Passweg, J. R. (2012). Hematopoietic
stem cell transplantation: a review
and recommendations for follow-
up care for the general practitioner.
Swiss. Med. Wkly. 142, w13696.
doi:10.4414/smw.2012.13696
Peffault de Latour, R., Rocha, V., and
Socie, G. (2013). Cord blood trans-
plantation in aplastic anemia. Bone
Marrow Transplant. 48, 201–202.
doi:10.1038/bmt.2012.252
Peiser, L., Mukhopadhyay, S., and
Gordon, S. (2002). Scavenger
receptors in innate immunity.
Curr. Opin. Immunol. 14, 123–128.
www.frontiersin.org May 2013 | Volume 4 | Article 126 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Domingo-Gonzalez and Moore Innate immune changes post-HSCT
doi:10.1016/S0952-7915(01)00
307-7
Peters, W. P., Stuart, A., Affronti, M.
L., Kim, C. S., and Coleman, R.
E. (1988). Neutrophil migration
is defective during recombinant
human granulocyte-macrophage
colony-stimulating factor infusion
after autologous bone marrow
transplantation in humans. Blood
72, 1310–1315.
Ramaprasad, C., Pouch, S., and
Pitrak, D. L. (2010). Neutrophil
function after bone marrow and
hematopoietic stem cell transplant.
Leuk. Lymphoma 51, 756–767.
doi:10.3109/10428191003695678
Reddy, P., Maeda,Y., Liu, C., Krijanovski,
O. I., Korngold, R., and Ferrara, J. L.
(2005). A crucial role for antigen-
presenting cells and alloantigen
expression in graft-versus-leukemia
responses. Nat. Med. 11, 1244–1249.
doi:10.1038/nm1309
Roychowdhury, M. (2005). Pulmonary
complications after bone marrow
transplantation: an autopsy study
from a large transplantation center.
Arch. Pathol. Lab. Med. 129,366–371.
Roziakova, L. (2011). Secondary malig-
nancies after hematopoietic stem cell
transplantation. Neoplasma 58, 1–8.
doi:10.4149/neo_2011_01_1
Rubin, P., Johnston, C. J., Williams,
J. P., McDonald, S., and Finkel-
stein, J. N. (1995). A perpetual cas-
cade of cytokines postirradiation
leads to pulmonary fibrosis. Int. J.
Radiat. Oncol. Biol. Phys. 33, 99–109.
doi:10.1016/0360-3016(95)00095-G
Sapru, K., Stotland, P. K., and Steven-
son, M. M. (1999). Quantitative
and qualitative differences in
bronchoalveolar inflammatory
cells in Pseudomonas aerugi-
nosa-resistant and -susceptible
mice. Clin. Exp. Immunol. 115,
103–109. doi:10.1046/j.1365-
2249.1999.00762.x
Sayers, T. J. (1988). Effect of
cytokines on polymorphonu-
clear neutrophil infiltration in
the mouse. Prostaglandin- and
leukotriene-independent induction
of infiltration by IL-1 and tumor
necrosis factor. J. Immunol. 141,
1670–1677.
Serezani, C. H., Aronoff, D. M., Jan-
car, S., Mancuso, P., and Peters-
Golden, M. (2005). Leukotrienes
enhance the bactericidal activity of
alveolar macrophages against Kleb-
siella pneumoniae through the acti-
vation of NADPH oxidase. Blood
106, 1067–1075. doi:10.1182/blood-
2004-08-3323
Soubani, A. O. (1996). Pulmonary com-
plications of bone marrow trans-
plantation. Chest 109, 1066–1077.
doi:10.1378/chest.109.4.1066
Soubani, A. O., Miller, K. B., and Has-
soun, P. M. (1996). Pulmonary com-
plications of bone marrow trans-
plantation. Chest 109, 1066–1077.
doi:10.1378/chest.109.4.1066
Soubani, A. O., and Uberti, J. P. (2007).
Bronchiolitis obliterans following
haematopoietic stem cell transplan-
tation. Eur. Respir. J. 29, 1007–1019.
doi:10.1183/09031936.00052806
Subramanian, K. K., Jia, Y., Zhu,
D., Simms, B. T., Jo, H., Hattori,
H., et al. (2007). Tumor sup-
pressor PTEN is a physiologic
suppressor of chemoattractant-
mediated neutrophil func-
tions. Blood 109, 4028–4037.
doi:10.1182/blood-2006-10-055319
Tarling, J. D., Lin, H. S., and Hsu,
S. (1987). Self-renewal of pul-
monary alveolar macrophages: evi-
dence from radiation chimera stud-
ies. J. Leukoc. Biol. 42, 443–446.
Therriault, B. L. (2010). Character-
ization of bacterial infections in
allogeneic hematopoietic stem cell
transplant recipients who received
prophylactic levofloxacin with
either penicillin or doxycycline.
Mayo Clin. Proc. 85, 711–718.
doi:10.4065/mcp.2010.0006
Tomita, Y. (1994). Myelosuppressive
conditioning is required to achieve
engraftment of pluripotent stem
cells contained in moderate doses of
syngeneic bone marrow. Blood 83,
939–948.
Tse, W. (2008). New insights into cord
blood stem cell transplantation.
Curr. Opin. Hematol. 15, 279–284.
doi:10.1097/MOH.0b013e328304ae2c
Versluys, A. B. (2010). Strong asso-
ciation between respiratory viral
infection early after hematopoietic
stem cell transplantation and the
development of life-threatening
acute and chronic alloimmune
lung syndromes. Biol. Blood Mar-
row Transplant. 16, 782–791.
doi:10.1016/j.bbmt.2009.12.534
Wang, Q. (2004). Neutrophils in innate
immunity. Semin. Respir. Crit. Care
Med. 25, 33–41. doi:10.1055/s-2004-
822303
Whittle, A. T., Davis, M., Shovlin,
C. L., Ganly, P. S., Haslett, C.,
and Greening, A. P. (2001). Alve-
olar macrophage activity and
the pulmonary complications of
haematopoietic stem cell trans-
plantation. Thorax 56, 941–946.
doi:10.1136/thorax.56.12.941
Wiltschke, C., Krainer, M., Nanut,
M., Wagner, A., Linkesch, W., and
Zielinski, C. C. (1995). In vivo
administration of granulocyte-
macrophage colony-stimulating
factor and granulocyte colony-
stimulating factor increases
neutrophil oxidative burst activity. J.
Interferon Cytokine Res. 15, 249–253.
doi:10.1089/jir.1995.15.249
Wingard, J. R., Hsu, J., and Hiemenz,
J. W. (2010). Hematopoietic
stem cell transplantation: an
overview of infection risks
and epidemiology. Infect. Dis.
Clin. North Am. 24, 257–272.
doi:10.1016/j.idc.2010.01.010
Winston, D. J., Territo, M. C., Ho,
W. G., Miller, M. J., Gale, R. P.,
and Golde, D. W. (1982). Alve-
olar macrophage dysfunction in
human bone marrow transplant
recipients. Am. J. Med. 73, 859–866.
doi:10.1016/0002-9343(82)90777-X
Wright, J. R. (2005). Immunoregula-
tory functions of surfactant pro-
teins. Nat. Rev. Immunol. 5, 58–68.
doi:10.1038/nri1528
Yang, S. (2000). Cyclophosphamide pre-
vents systemic keratinocyte growth
factor-induced up-regulation of sur-
factant protein A after allogeneic
transplant in mice. Am. J. Respir.
Crit. Care Med. 162, 1884–1890.
doi:10.1164/ajrccm.162.5.2002053
Yu, H. (2000). Innate lung defenses and
compromised Pseudomonas aerugi-
nosa clearance in the malnourished
mouse model of respiratory
infections in cystic fibrosis.
Infect. Immun. 68, 2142–2147.
doi:10.1128/IAI.68.4.2142-
2147.2000
Zimmerli, W., Zarth, A., Gratwohl, A.,
and Speck, B. (1991). Neutrophil
function and pyogenic infections in
bone marrow transplant recipients.
Blood 77, 393–399.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 01 April 2013; accepted: 13 May
2013; published online: 24 May 2013.
Citation: Domingo-Gonzalez R and
Moore BB (2013) Defective pulmonary
innate immune responses post-stem cell
transplantation; review and results from
one model system. Front. Immunol.
4:126. doi: 10.3389/fimmu.2013.00126
This article was submitted to Frontiers in
Inflammation, a specialty of Frontiers in
Immunology.
Copyright © 2013 Domingo-Gonzalez
and Moore. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Immunology | Inflammation May 2013 | Volume 4 | Article 126 | 10
